• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 Trial.

作者信息

Patel Siddharth M, Bonaca Marc P, Morrow David A, Palazzolo Michael G, Jarolim Petr, Steg Philippe Gabriel, Bhatt Deepak L, Storey Robert F, Sabatine Marc S, O'Donoghue Michelle L

机构信息

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

University of Colorado School of Medicine, Aurora, CO.

出版信息

JACC Adv. 2023 Nov;2(9). doi: 10.1016/j.jacadv.2023.100675. Epub 2023 Oct 28.

DOI:10.1016/j.jacadv.2023.100675
PMID:38106527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10723808/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ad/11198547/a96c32872652/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ad/11198547/a96c32872652/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ad/11198547/a96c32872652/gr1.jpg

相似文献

1
Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 Trial.脂蛋白(a)与抗血小板治疗的获益：来自PEGASUS-TIMI 54试验的见解
JACC Adv. 2023 Nov;2(9). doi: 10.1016/j.jacadv.2023.100675. Epub 2023 Oct 28.
2
Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria.针对符合PEGASUS-TIMI 54标准的急性心肌梗死患者长期使用双联抗血小板治疗的临床获益。
Front Cardiovasc Med. 2022 Nov 17;9:1017533. doi: 10.3389/fcvm.2022.1017533. eCollection 2022.
3
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.既往心肌梗死患者停用 P2Y12 抑制剂后时间与替格瑞洛缺血风险和疗效的关系：来自 PEGASUS-TIMI 54 的见解。
Eur Heart J. 2016 Apr 7;37(14):1133-42. doi: 10.1093/eurheartj/ehv531. Epub 2015 Oct 21.
4
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.长期使用替格瑞洛对既往有心肌梗死且无冠状动脉支架置入史患者进行二级预防：来自PEGASUS-TIMI 54研究的见解
Eur Heart J. 2020 May 1;41(17):1625-1632. doi: 10.1093/eurheartj/ehz821.
5
Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry.应用 PEGASUS-TIMI 54 试验纳入标准对“真实世界”STEMI 人群进行风险定义和结局评估：来自意大利“CARDIO-STEMI SANREMO”注册研究的结果。
BMC Cardiovasc Disord. 2021 Mar 18;21(1):144. doi: 10.1186/s12872-020-01780-y.
6
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.心肌梗死后的长期抗血小板治疗：PEGASUS-TIMI 54研究的启示
Heart. 2016 May 15;102(10):783-9. doi: 10.1136/heartjnl-2015-307858. Epub 2016 Feb 8.
7
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.高危心肌梗死患者接受延长抗血小板治疗的患病率及预后
Rev Esp Cardiol (Engl Ed). 2016 May;69(5):480-7. doi: 10.1016/j.rec.2015.12.022. Epub 2016 Apr 7.
8
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.替格瑞洛对比安慰剂用于阿司匹林-溶栓治疗心肌梗死 54 患者（PEGASUS-TIMI 54 试验）预防心血管事件的设计和原理。
Am Heart J. 2014 Apr;167(4):437-444.e5. doi: 10.1016/j.ahj.2013.12.020. Epub 2014 Jan 6.
9
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.PEGASUS-TIMI 54 试验中既往冠状动脉支架置入患者的长期替格瑞洛治疗。
J Am Heart Assoc. 2021 Sep 7;10(17):e020446. doi: 10.1161/JAHA.120.020446. Epub 2021 Aug 21.
10
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).替格瑞洛治疗心肌梗死后患者预防中风：PEGASUS-TIMI 54 研究的见解（在阿司匹林-溶栓治疗心肌梗死 54 研究背景下，与安慰剂相比，替格瑞洛用于既往心肌梗死患者预防心血管事件的疗效）。
Circulation. 2016 Sep 20;134(12):861-71. doi: 10.1161/CIRCULATIONAHA.116.024637. Epub 2016 Aug 30.

引用本文的文献

1
The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level: a case report.极高脂蛋白(a)水平下二级心血管预防的挑战：一例报告
Eur Heart J Case Rep. 2025 Aug 9;9(9):ytaf389. doi: 10.1093/ehjcr/ytaf389. eCollection 2025 Sep.
2
2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.2024年：心血管疾病之年——脂蛋白(a)之年。研究进展与新发现。
Arch Med Sci. 2025 Feb 22;21(2):355-373. doi: 10.5114/aoms/202213. eCollection 2025.
3
Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening.

本文引用的文献

1
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes.脂蛋白(a)基因型与阿司匹林用于心血管事件一级预防的关系。
J Am Coll Cardiol. 2022 Oct 4;80(14):1287-1298. doi: 10.1016/j.jacc.2022.07.027.
2
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.脂蛋白(a)与动脉粥样硬化性心血管疾病及主动脉瓣狭窄：欧洲动脉粥样硬化学会共识声明。
Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.
3
Long-term use of ticagrelor in patients with prior myocardial infarction.
重新审视心血管风险：脂蛋白(a)筛查的新作用。
Am J Prev Cardiol. 2025 Feb 14;21:100945. doi: 10.1016/j.ajpc.2025.100945. eCollection 2025 Mar.
4
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk.脂蛋白(a)的个体内变异性：重复测量对重新分类中度风险个体的价值。
Eur Heart J Open. 2024 Aug 31;4(5):oeae064. doi: 10.1093/ehjopen/oeae064. eCollection 2024 Sep.
5
Strategies for management of patients with elevated lipoprotein(a).脂蛋白(a)升高患者的管理策略。
Curr Opin Lipidol. 2024 Oct 1;35(5):234-240. doi: 10.1097/MOL.0000000000000950. Epub 2024 Aug 14.
6
Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial revascularization.小载脂蛋白(a)异构体可能预测外周动脉血运重建后的原发性通畅情况。
JVS Vasc Sci. 2024 Jun 11;5:100211. doi: 10.1016/j.jvssci.2024.100211. eCollection 2024.
7
Lipoprotein(a): Emerging insights and therapeutics.脂蛋白(a)：新见解与治疗方法
Am J Prev Cardiol. 2024 Mar 29;18:100641. doi: 10.1016/j.ajpc.2024.100641. eCollection 2024 Jun.
8
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.脂蛋白(a)与基线有或无动脉粥样硬化性心血管疾病患者的主要不良心血管事件。
J Am Coll Cardiol. 2024 Mar 5;83(9):873-886. doi: 10.1016/j.jacc.2023.12.031.
既往心肌梗死患者中长期使用替格瑞洛。
N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.
4
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.载脂蛋白(a)基因多态性、血浆脂蛋白(a)、心血管疾病与低剂量阿司匹林治疗
Atherosclerosis. 2009 Apr;203(2):371-6. doi: 10.1016/j.atherosclerosis.2008.07.019. Epub 2008 Jul 26.